You are here
The field of molecular imaging is grazed by two different animals—the workhorses, such as SPECT, PET and tried-and-true biomarkers like FDG, and the young, intrepid and unpredictable newcomers that have been given a name, taken around the track a couple times, but perhaps are still too fresh to be saddled with the responsibility of routine clinical use. These are the innovations in dementia and psychiatric imaging, hybrid and optical-acoustic modalities and anatomy-specific precision biomarkers. While the herd of the latter is extensive, only a few are notable enough to include here amongst the most promising workhorses five or more years from now. What technologies and biomarkers are going to make it through the gate to race into clinical practice?
Molecular Imaging Insight...